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Purpose or Objective: Short-course radiotherapy (25 Gy in 
five fractions) was recently shown in a multi-national 
randomized phase III clinical trial to be non-inferior to a 
commonly used regimen (40 Gy in 15 fractions) in elderly 
and/or frail patients with glioblastoma multiforme, with no 
difference in overall survival (OS) and progression free 
survival (PFS). This study compared the cost-effectiveness of 
the two regimens. 
 
Material and Methods: The direct unit costs of imaging, 
radiotherapy (RT), and dexamethasone were collected in 
equitable US dollars (USD) from the five primary contributing 
countries to the trial, representing 88% of all patients 
accrued (n = 86) between 2010 and 2013. Effectiveness was 
measured by the restricted mean overall survival (RMOS) and 
progression free survival (RMPFS). Irwin’s restricted mean 
method was used to calculate mean survival time in the 
presence of censoring, and life-years gained and PFS gained. 
The incremental cost-effectiveness ratio (ICER) was 
calculated as: Cost per life-year gained = (Difference in 
direct costs between short-course RT and commonly used RT) 
÷ (Difference in life-years gained between short-course RT 
and commonly used RT). Indirect costs were also estimated 
for comparison. 
 
Results: There was no OS difference between the two 
studied populations. The median OSs for the short-course and 
commonly used RTs were 8.2 (6.1-10.3) and 7.7 (5.5-9.9) 
months, respectively. Median PFSs were also not different. 
The differences in the RMOS and the ICER, however, were 
+0.11 life-years and -USD 3307 per life-year gained, 
respectively. The differences in the RMPFS and the ICER were 
+0.02 PFS and -USD 19030, respectively. The negative ICER 
values indicated improvement in direct cost in addition to 
life-years gained with the short-course RT. Indirect cost 
comparison also identified improved survival-to-treatment 
time ratio and reduced cost for patients and care-givers with 
short-course RT.  
 
Conclusion: The direct cost account for ICER of -USD 3307 
per life-year gained and -USD 19030 per PFS gained indicates 
that the short-course RT is less costly and more effective 
compared to the commonly used RT. Indirect cost is also 
improved with the short-course RT.  
 
 
 
 
 
OC-0533  
TGUGT and G8 tests predicting frailty and radiotherapy 
compliance and acute toxicity in the elderly 
J. Middelburg
1Erasmus Medical Center, Radiotherapy, Rotterdam, The 
Netherlands 
1, T. Rozema2, H. Maas3, E. Baartman1, M. 
Aarts4, D. Geijsen5, A. Leest6, J. Jobsen7, J. Coebergh8, H. 
Struikmans9 
2Institute Verbeeten, Radiotherapy, Tilburg, The Netherlands 
3Tweesteden Hospital, Geriatrics, Tilburg, The Netherlands 
4Netherlands Comprehensive Cancer Organisation IKNL, 
Netherlands Cancer Registry, Utrecht, The Netherlands 
5Academic Medical Center, Radiotherapy, Amsterdam, The 
Netherlands 
6University Medical Center Groningen, Radiotherapy, 
Groningen, The Netherlands 
7Medisch Spectrum Twente, Radiation Oncology, Enschede, 
The Netherlands 
8Erasmus Medical Center, Public Health, Rotterdam, The 
Netherlands 
9Medical Center Haaglanden, Radiotherapy Center West, Den 
Haag, The Netherlands 
 
Purpose or Objective: On behalf of the LPRO (National 
organisation for radiotherapy in the elderly): 
The incidence of cancer increases with age. Older cancer 
patients are often underrepresented in clinical trials. 
Reliable predicting tools for toxicity and compliance of 
radiotherapy are not yet available. The G8 is a screening tool 
developed for older cancer patients. The “Timed Get Up and 
Go Test” (TGUGT) is a validated test for quantifying the 
degree of mobility. In the current study we aim to quantify to 
which extend the G8 and the TGUGT are predictive for both 
radio(chemo)therapy compliance and acute toxicity of 
curative radiotherapy in elderly cancer patients. 
 
Material and Methods: Patients were recruited in seven 
Dutch radiotherapy centers: if they were 65 years and older, 
had newly diagnosed breast/ NSCLC/prostate/head and neck/ 
rectal and oesophageal cancer, were referred for 
radio(chemo)therapy with curative intent between April 2015 
and the end of October 2015, and had no history of prior 
radiotherapy. The TGUGT test (normal: ≤10 seconds, frail 
elderly: 11-20 seconds, and needs further evaluation: >20 
seconds) and the G8 score (≤14 is indicative of frailty in older 
cancer patients) were performed before starting the 
radiotherapy. Compliance with radio- and or 
radio/chemotherapy and acute toxicity (< 3 months after 
ending the radiotherapy) were recorded. 
 
Results: A total of 335 patients were included, of which 53% 
were male. The mean age was 72.8 and 4% were 85 year or 
older. WHO scores were 0 for 55%, 1 for 36%, 2 for 8%, 3 for 
0.3% and unknown in 1%. Patients were motivated to 
participate, with a mean score of 9.1 and a median of 10, on 
a ten point scale. Forty-three percent of the patients were 
considered frail based on the G8 score and 18% based on the 
TGUGT test. There was an association between the G8 and 
the TGUGT, with every point increase of the G8 
corresponding to walking 0.4 seconds faster. Comorbidity was 
associated with lower G8 scores, difference 1.3 (95% 
confidence interval (CI): 08.to 1.8) and slower TGUGT, 
difference 1.5 (CI: 0.8 to 2.2). Follow-up is still ongoing but 
will be completed before the end of January 2016. Full 
results will be presented at the ESTRO 35. Until now (n=57) 
the compliance is high. All patients completed treatment 
according to protocol. Acute toxicity is low with 5% grade 3. 
No grade 4 or 5 toxicity was observed. 
 
Conclusion: We observed an association between the results 
from G8 and TGUGT. Associations between test results and 
toxicity and compliance will be presented. 
 
 
 
 
 
 
